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Background: Selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are reported to have potent
antiemetic effects for postoperative nausea and vomiting (PONV). The purpose of this study was to prospectively
evaluate the efficacy of palonosetron, granisetron, and ramosetron for the prevention of PONV in patients
undergoing laparoscopic gynecologic surgery.
Methods: In this prospective, randomized observational study, 105 healthy female patients who were undergoing
laparocopic hystectomy under general anaesthesia were enrolled (clinical trial number: NCT01752374,
www.clinicaltrials.gov). Patients were divided into three groups: the palonostron (0.075 mg i.v.; n = 35), the
granisetron group (3 mg i.v.; n = 35), and the ramosetron group (0.3 mg i.v.; n = 35). The treatments were given
before the end of surgery. The incidence of PONV, severity of nausea/vomiting, and the use of rescue antiemetic
requirements during the first 48 h after surgery were evaluated.
Results: The overall incidence of PONV was 33.3 % for this series. The number of complete responders at 48 h after
the surgery was 21 (60.0 %) for palonosetron, 24 (68.6 %) for granisetron, and 26 (71.4 %) for ramosetron,
representing no statistical difference (P = 0.086).
Conclusions: There were no significant differences in the overall incidence of postoperative nausea and vomiting
and complete responders for palonosetron, granisetron and ramosetron group.
Trial registration: Clinical trial number: NCT01752374, www.clinicaltrials.gov.Background
Laparoscopic surgeries are the second most common
cause of postoperative nausea and vomiting (PONV), a
frequent and disturbing complication of surgery and
anesthesia [1]. The incidence of PONV after gynecological
laparoscopy is reported to be nearly 80 % [2] and can
result in prolonged hospital stay and recovery times.
Numerous antiemetics have been studied to prevent
and treat PONV after laparoscopic abdominal surgery,* Correspondence: gachonlws@gmail.com
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able side effects such as sedation, dry mouth and
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Selective serotonin 5-hydroxytryptamine type 3 (5-HT3)
receptor antagonists have a well-established role in the
prophylaxis and treatment of PONV due to their efficacy
and fewer side effects compared to other antiemetics [6].
Most 5-HT3 receptor antagonist research has focused on
ondansetron, and the antiemetic efficacy of these com-
pounds has been well established for the prevention and
treatment of chemotherapy-induced emesis, as well as for
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a relatively short half-life of 4 to 9 h. Ramosetron is a re-
cently developed selective 5-HT3 receptor antagonist,
which exhibits a significantly greater binding affinity for
5-HT3 receptors and a slower dissociation rate com-
pared to older 5-HT3 receptor antagonists, resulting in
more potent and longer effects. Palonosetron is a
second-generation 5-HT3 receptor antagonist with an
even higher receptor binding affinity, and a prolonged
mean half-life of about 40 h [8]. We hypothesized that
long acting palonosetron treatment would be more
effective in lowering the incidence of PONV, compared
to treatment with granisetron and ramosetron. The
purpose of this study was to prospectively evaluate
the efficacy of palonosetron, granisetron, and ramosetron
in the prevention of PONV in patients undergoing laparo-
scopic gynecologic surgery.Methods
Inclusion criteria
The study proposal was finalized and approved by
Gachon University, Gil Hospital institutional review
board before the investigation was initiated. Written in-
formed consent was acquired from all participants be-
fore enrollment in the study. This investigator-initiated,
prospective, non-blinded, randomized controlled trial
was performed at Gachon University, Gil Hospital
between November 2011 and June 2013. Using a random
number table, patients were randomly assigned to receive
palonosetron (n = 35), ramosetron (n = 35), or granisetron
(n = 35; Fig. 1).Fig. 1 Patient allocationExclusion criteria
Exclusion criteria were as follows: Allergy to any of the
experimental drugs, opioid dependence, a history of
PONV and motion sickness, use of antiemetic medica-
tion within 24 h prior to surgery, pregnancy, inability to
use the patient controlled analgesia (PCA) IV device or
to comprehend the 10 cm visual analogue scales (VAS;
0, none; 10, maximum) for pain and nausea assessment,
and unwillingness to be enrolled in the study.
Study protocol
All patients received intramuscular midazolam (0.05 mg/
kg) and glycopyrrolate (0.2 mg) as premedication 1 h be-
fore anesthesia induction. In the operating room, the vital
signs of the patient were continuously monitored using
electrocardiogram, pulse oximetry, and measurement of
noninvasive arterial pressure. Anesthesia was induced and
maintained with propofol (target effect site concentration
2.5–3.5 μg/ml) and remifentanil (target effect site concen-
tration 2.5–5.0 ng/ml) using a target controlled infusion
(TCI) pump (Orchestra®, Fresenius Vial, Brezins, France).
Rocuronium (0.6 mg/kg) was administered to facilitate tra-
cheal intubation. Anesthesia was maintained with sevoflur-
ane (0.5 ─5 %) and nitric oxide (50 %) throughout surgery.
All patients were ventilated using an S/5 Avance
anesthetic machine (GE Healthcare, Madison, WI). After
anesthesia induction, patients were mechanically venti-
lated with constant flow and I:E ratio of 1:2, and tidal vol-
ume (TV) set at 8 ml/kg of ideal body weight. Respiratory
rate was adjusted to 8–20 breaths/min to maintain
end-tidal carbon dioxide concentration (ETCO2) of
30–40 mmHg at 60 % inspired oxygen with air [9].
Table 1 Patient characteristics (n = 105)
Palonosetron
group, n = 35
Granisetron
group, n = 35
Ramosetron
group, n = 35
P-value
Age, year 51.5 ± 16.3 52.5 ± 15.7 48.2 ± 12.1 0.42
Height (cm) 155.3 ± 3.1 157.1 ± 6.1 157.2 ± 3.3 0.65
Weight (kg) 60.1 ± 4.9 59.3 ± 5.1 56.3 ± 4.3 0.55
Operation
Time(min)
100.2 ± 34.1 99.4 ± 25.3 92.6 ± 24.9 0.46
Anesthesia
Time(min)
128.1 ± 47.5 123.5 ± 35.1 120.1 ± 23.0 0.63
Fluid Admin(mL) 522.1 ± 61.2 644 ± 33.3 538 ± 53.9 0.75
ASA class I/II 23/12 24/11 26/9 0.67
Comorbid dis. 0.56
Hypertension 7 8 8
Diabetes 3 3 4
Othera 1 0 1
aOther comorbid diseases include: Fatty liver, Rheumatoid arthritis
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ess needle technique, and the intra-abdominal pressure
was maintained at 12–14 mmHg. After CO2 insufflation,
patients were placed in the reverse Trendelenburg position
at 20°. Laparoscopic gynecologic surgery was performed
through two ports of 10 mm and two ports of 5 mm in the
standard position with the legs closed [9].
Patients received a single dose of palonosetron
0.075 mg, granisetron 3 mg, or ramosetron 0.3 mg intra-
venously (IV) at the end of the surgery, prior to extuba-
tion. The experimental medications were prepared in
identical 5 cc syringes and administered according to
protocol by a nurse. For postoperative pain control,
diclofenac 75 mg was administered intramuscularly (IM)
at the start of wound closure, and repeated upon patient
request. The incidence of nausea and vomiting was re-
corded during the assessment periods by ward nursing
staff not blinded to the treatment drugs.
Nausea was defined as a subjectively unpleasant sensa-
tion associated with the urge to vomit. Incidences of
vomiting included retching (defined as the labored, spas-
tic, rhythmic contraction of the respiratory muscles
without expulsion of the gastric contents) and actual
vomiting (defined as the forceful expulsion of gastric
contents from the mouth). A complete response to
palonosetron, granisetron, and ramosetron was de-
fined as an absence of PONV and no need for further
rescue antiemetic drugs. A rescue antiemetic (10 mg
metoclopramide) was administered IV upon patient
request, if two or more episodes of PONV occurred
during the study period, if nausea intensity increased
from moderate to severe (VAS > 5) and on vomiting.
The primary outcome was incidence of complete re-
sponders during the study period. Details of any other
adverse effects such as headache and dizziness were
also collected. All data were collected by a dedicated
research nurse at 6, 24, and 48 h after surgery.
Statistical analyses
Sample size was calculated using two proportions power
analysis on the basis of the primary outcome measure. It
was estimated that 30 patients per group would be re-
quired for the power analysis (for a power of 80 % and a
type 1 error of 5 %) to demonstrate a relative reduction
of 25 % in complete response in each group 48 h after
surgery. This calculation was based on previously
published studies [10, 11]. Student’s t-test was used to
compare the inter-group differences, and a chi-square
test was used for categorical variables. P-values were
corrected using the Bonferroni method. Values are
expressed as counts or the mean ± standard deviation.
P-values < 0.05 were considered statistically significant.
All patients underwent laparoscopic hysterectomy
under general anesthesia.Results
All patients completed the study. Patient characteristics
and basic operative data are presented in Table 1. A total
of 125 patients were screened to assess their eligibility
for this trial (Fig. 1) and 105 patients were enrolled in
the study. The groups were comparable with respect to
age, weight, duration of surgery, and ASA score. The
overall incidence of PONV was 19.3 %. The incidence of
nausea was highest during the first 6 h (total incidence
of 18.1 %) and decreased throughout the study period.
The number of complete responders at 48 h after the
surgery was 21 (60.0 %) for palonosetron, 24 (68.6 %) for
granisetron, and 26 (74.3 %) for ramosetron. The differ-
ences between the groups were not statistically significant
(P = 0.086, Table 2). All three groups were comparable
across the time intervals examined.
The number of subjects in each of the three study
groups experiencing at least one episode of vomiting
within the three time intervals is shown in Table 2. More
subjects suffered vomiting in the early phase (0–6 h) of
postoperative period in the palonosetron and ramose-
tron groups compared with the granisetron group, which
had no vomiting during this period. However, this differ-
ence was not statistically significant.
The incidence of most of the common adverse events,
such as headache and dizziness, was similar among the
three groups, and no clinically significant treatment-
related adverse events were observed.Discussion
In the present study, all three antiemetics were shown to
be equally effective in preventing nausea and vomiting.
There were no statistically significant differences in the
Table 3 Results of studies evaluating outcomes of PONV














Yun et al. No 98 2010 Az, On 35-51
Ryu et al. No 120 2010 On, Ra 23-40
Fujii et al. Yes 120 1999 Ra, Gr 87-90
Swaika et al. Yes 87 2011 Ra, Pa 38-66
Current study Yes 105 2012 Pa, Ra, On 60-71
Az azasetron; On ondansetron; Pa palonostron; Ra ramosetron; Gr graniestron
Table 2 Number of nausea and vomiting over time in the three
study groups (n = 105)
Palonosetron
group,
n = 35 (%)
Granisetron
group,
n = 35 (%)
Ramosetron
group,
n = 35 (%)
P-value
0-6 h
Nausea 6 (17.1) 5 (14.2) 6 (17.1) 0.87
Vomiting 1 (2.9) 0 (0) 1 (2.9) N/A
Rescue drug 2 (5.7) 1 (2.9) 1 (2.9) 0.69
6-24 h
Nausea 3 (8.6) 4 (11.4) 4 (11.4) 0.73
Vomiting 1 (2.9) 0 (0) 0 (0) N/A
Rescue drug 1 (2.9) 0 (0) 0 (0) N/A
24-48 h
Nausea 2 (5.7) 1(2.9) 1 (2.9) 0.43
Vomiting 0 (0) 0 (0) 0 (0) N/A
Rescue drug 0 (0) 0 (0) 0 (0) N/A
No. complete
responder
21, 60.0 % 24, 68.6 % 26,74.3 % 0.086
N/A; not applicable due to small number of samples
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groups. A variety of 5-HT3 antagonists have been used
to manage PONV [12]. It is generally accepted that all
5-HT3 antagonists have a similar mechanism of action
(selective or competitive binding to 5-HT3 receptors) as
well as comparable efficacy and safety profiles [5, 10].
This is the first direct comparison between these three
antiemetics for their role in case of laparoscopic gyneco-
logic surgery.
The reported incidence of PONV is 30 to 80 % within
the first 24 h after laparoscopic surgery when no
prophylactic antiemetic is administered [5, 3, 13]. The
present study reports an overall incidence of 33.3 %
within the first 48 h post-surgery, without any statistical
difference between the three groups. The high incidence
during the first 24 h of surgery may be explained by the
central action of carbon dioxide (CO2), stretching of the
peritoneum and diaphragm, and increased blood pres-
sure in the peritoneal cavity after CO2 insufflation dur-
ing laparoscopic surgery, as previously reported by Ryu
et al. [3]. All these factors are considered to provoke
nausea and vomiting by reducing the blood flow and releas-
ing emetogenic substances, including serotonin [14, 15].
The reported efficacy of ramosetron for the prevention
of chemotherapy-induced emesis is similar to that of
granisetron [16]. However, ramosetron appears to have a
longer duration of action; its effects last for 24 h after
cisplatin-based chemotherapy [17]. Pal et al. [18] found
that ramosetron is also more effective than palonosetron
and ondansetron during the early postoperative period.
However, we did not find any significant difference
between patients treated with these compounds in thepresent study. Of note, we used remifentanil to achieve the
desired analgesic effect. Remifentanil infusion during des-
flurane- or propofol-induced anesthesia facilitates early
recovery without immensely increasing PONV, pain or the
need for rescue medication after laparoscopic surgery [19].
We are unaware of any published study simultaneously
evaluating the efficacy of palonosetron, granisetron, and
ramosetron. Discrepancies exist between studies examin-
ing the effects of each 5-HT3 antagonist individually
[20]. To the best of our knowledge, ours is the first study
to evaluate the efficacy of palonosetron, granisetron, and
ramosetron as prophylactics for preventing PONV in
patients undergoing uniform laparoscopic gynecologic
surgery. Aspinall and Goodman suggested that if active
drugs are available, placebo-controlled trials are uneth-
ical because PONV is a very disturbing and distressing
event that can occur after laparoscopic surgery [20]. In
the current study, three commercially available 5-HT3
antagonists were used as antiemetics to prevent PONV
after laparoscopic surgery. We found that the three
agents yielded similar numbers of complete responses
(i.e., no postoperative nausea or vomiting and no rescue
antiemetic administration required) between 0 and 48 h
after surgery.
We observed relatively similar numbers of complete
responders in each group, in contrast with previously
published reports (Table 3). The most frequently reported
adverse events of 5-HT3 receptor antagonists are dizziness
and headache [6]. The adverse events observed in our
study were similar among all three groups of patients.
The major limitations of the current study are: (1) We
compared the efficacy of palonosetron, ramosetron, and
granisetron at their known optimal doses, not at equipo-
tent doses, and (2) this was not a double-blinded study.
We did not administer equipotent doses of the com-
pounds as they were unknown at the time of commence-
ment of the study. Investigations on a larger scale are
needed to assess the equipotency of palonosetron, ramo-
setron, and granisetron.
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In conclusion, our study demonstrated that palonose-
tron, ramosetron, and granisetron are equally effective as
antiemetics against postoperative nausea and vomiting
in patients undergoing laparoscopic gynecologic surgery.
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